Evaluation of insulin-like growth factor II, cyclooxygenase-2, ets-1 and thyroid-specific thyroglobulin mRNA expression in benign and malignant thyroid tumours

European Journal of Endocrinology

Volumn 152, Issue 5, 2005, Pages 785-790

  Fuhrer, D ^a   Eszlinger, M ^a   Karger, S ^a   Krause, K ^a   Engelhardt, C ^a   Hasenclever, D ^a   Dralle, H ^b   Paschke, R ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; MESSENGER RNA; SOMATOMEDIN B; THYROGLOBULIN; TRANSCRIPTION FACTOR ETS 1;

ARTICLE; ASPIRATION BIOPSY; CONTROLLED STUDY; DIAGNOSTIC VALUE; FOLLICULAR CARCINOMA; GENE EXPRESSION; GRAVES DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PAPILLARY CARCINOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THYROID CANCER; THYROID NODULE; THYROID TUMOR; TUMOR DIFFERENTIATION;

ADENOMA; CYCLOOXYGENASE 2; GENE EXPRESSION REGULATION, NEOPLASTIC; GRAVES DISEASE; HUMANS; INSULIN-LIKE GROWTH FACTOR II; MEMBRANE PROTEINS; POLYMERASE CHAIN REACTION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTO-ONCOGENE PROTEIN C-ETS-1; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-ETS; RNA, MESSENGER; THYROGLOBULIN; THYROID GLAND; THYROID NEOPLASMS; THYROID NODULE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 19744368505     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.01912     Document Type: Article

References (18)

1. Rojeski MT & Gharib H. Nodular thyroid diesase. Evaluation and management. New England Journal of Medicine 1985 313 428-436.
2. Mazzaferri EL. Management of a solitary thyroid nodule. New England Journal of Medicine 1993 328 553-559.
3. Krohn K, Führer D, Bayer Y, Eszlinger M, Brawr V, Neumann S & Paschke K. Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocrine Reviews 2004 [Epub].
4. Gharib H. Changing concepts in the diagnosis and management of thyroid nodules. Endocrinology and Metabolism Clinics of North America 1997 26 777-800.
5. Oertel YC. A pathologist trying to help endocrinologists to interpret cytopathology reports from thyroid aspirates. Journal of Clinical Endocrinology and Metabolism 2002 87 1459-1461.
6. Fagin A. Minireview: branded from the start - distinct oncogenic initiating events may determine tumor fate in the thyroid. Molecular Endocrinology 2002 16 903-911.
7. Kroll TG, Sarraf P, Pecciarini L, Chen C-J, Mueller E, Spiegelmann BM & Fletcher JA. PAXB-PPAR gamma 1 fusion ancogene in human thyroid carcinoma [corrected]. Science 2000 289 1357-1360.
8. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW II, Tallini G, Kroll TG & Nikiforova YE, RAS point mutations and PAXP-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. Journal of Clinical Endocrinology and Metabolism 2003 88 2318-2326.
9. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, Inohara H, Marandino P, Orlandi F, Nardi F, Vecchione A, Tecce R & Larsson O. Thyroid Cancer Study Group. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001 357 1644-1650.
10. Niedziela M, Maceluch J & Korman E. Galectin-3 is not an universal marker of malignancy in thyroid nodular disease in children and adolescents. Journal of Clinical Endocrinology and Metabolism 2002 87 4411-4415.
11. Vella V, Pandini G, Sciacca L, Mineo R, Squatrito S, Vigneri R & Belficre A. A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2002 87 245-254.
12. Ito Y, Yoshida H, Nakano K, Takmura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Matsuura N, Kuma K & Miyauchi A Cyclooxygenase-2 expression in thyroid neoplasms. Histopathology 2003 42 492-497.
13. Specht MC, Tucker ON, Hocever M, Gonzalez D, Teng L & Fahey TJ 3rd. Cyclooxygenase-2 expression in thyroid nodules. Journal of Clinical Endocrinology and Metabolism 2002 87 358-363.
14. de Nigris F, Mega T, Berger N, Barone MV, Santoro M, Viglietto G, Verde P & Fusco A. Induction of ETS-1 and ETS-2 transcription factors is required for thyroid cell transformation. Cancer Research 2001 61 2267-2275.
15. Eszlinger M, Neumann S, Otto L & Paschke R Thyroglobulin mRNA quantification in the peripheral blood is not a reliable marker for the follow-up of patients with differentiated thyroid cancer. European Journal of Endocrinology 2002 147 575-582.
16. Eszlinger M, Krohn K, Berger K, Läuter J, Kropf S, Beck M, Fuhrer D & Paschke R. Gene expression analysis reveals increased expression of cell cycle associated genes and Gq protein kinase signalling in cold thyroid nodules. Journal of Clinical Endocrinology and Metabolism 2005 90 1163-1170.
17. Chang CH, Scott GK, Kuo WL, Xiong X, Suzdaltseva Y, Park JW, Sayer P, Erny K, Collins C, Gray JW & Benz CC. ESX: a structurally unique ets overexpressed early during human breast tumorigenesis. Oncogene 1997 14 1617-1622.
18. Lazar V, Bidart JM, Caillou B, Mahe C, Lacroin L, Filetti S & Schlumberger M Expression of the Na/I symporter gene in human thyroid tumours: a comparison study with other thyroid-specific genes. Journal of Clinical Endocrinology and Metabolism 1999 84 3228-3234.